skip to content »

Section of Atherosclerosis

Houston, Texas

BCM faculty, staff and trainees are the heart of the organization.
Section of Atherosclerosis and Vascular Medicine
not shown on screen

Publications 2003

Ballantyne CM. Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the Heart Protection Study on standards of efficacy and safety. Am J Cardiol. 2003 Aug 21;92(4B):3K-9K.

Ballantyne CM, Blazing MA, Hunninghake DB, Davidson MH, Yuan Z, DeLucca P, Ramsey KE, Hustad CM, Palmisano J. Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). Am Heart J. 2003 Nov;146(5):862-9.

Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, Marz W, Reckless JP, Stein EA. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003 Mar 10;163(5):553-64.

Ballantyne CM, Davidson MH. Possible differences between fibrates in pharmacokinetic interactions with statins. Arch Intern Med. 2003 Oct 27;163(19):2394-5.

Ballantyne CM, Hoogeveen RC. Role of lipid and lipoprotein profiles in risk assessment and therapy. Am Heart J. 2003 Aug;146(2):227-33.

Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP; Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003 May 20;107(19):2409-15.

Ballantyne CM, Stein EA, Paoletti R, Southworth H, Blasetto JW. Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. Am J Cardiol. 2003 Mar 6;91(5A):25C-27C.

Borjesson DL, Simon SI, Hodzic E, DeCock HE, Ballantyne CM, Barthold SW. Roles of neutrophil beta 2 integrins in kinetics of bacteremia, extravasation, and tick acquisition of Anaplasma phagocytophila in mice. Blood. 2003 Apr 15;101(8):3257-64.

Case CC, Jacobson TA, Roberts S, Buckley A, Murtaugh KM, Sung JC, Gause D, Varas C, Ballantyne CM. Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol. Am J Cardiol. 2003 May 1;91(9):1134-6.

Chakraborty BM, Mueller WH, Reeves R, Poston WS 2nd, Holscher DM, Quill B, Hanis CL, Foreyt JP. Migration history, health behaviors, and cardiovascular disease risk factors in overweight Mexican-American women. Ethn Dis. 2003 Winter;13(1):94-108.

Chakraborty BM, Mueller WH, Reeves R, Holscher DM, Quill B, Poston WS 2nd, Hanis CL, Foreyt JP. For the patient. The importance of health behaviors for better heart health. Migration history, health behaviors, and cardiovascular disease risk factors in overweight Mexican-American women. Ethn Dis. 2003 Winter;13(1):152.

Chen CH, Jiang T, Yang JH, Jiang W, Lu J, Marathe GK, Pownall HJ, Ballantyne CM, McIntyre TM, Henry PD, Yang CY. Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation. 2003 Apr 29;107(16):2102-8.

Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, Hoogeveen R, Folsom AR, Heiss G; Atherosclerosis Risk in Communities Study. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2003 Jul;52(7):1799-805.

Dunne JL, Collins RG, Beaudet AL, Ballantyne CM, Ley K. Mac-1, but not LFA-1, uses intercellular adhesion molecule-1 to mediate slow leukocyte rolling in TNF-alpha-induced inflammation. J Immunol. 2003 Dec 1;171(11):6105-11.

Fernandes LS, Conde ID, Wayne Smith C, Kansas GS, Snapp KR, Bennet N, Ballantyne C, et al. Platelet-monocyte complex formation: effect of blocking PSGL-1 alone, and in combination with alphaIIbbeta3 and alphaMbeta2, in coronary stenting. Thromb Res. 2003;111(3):171-7.

Folsom AR, Desvarieux M, Nieto FJ, Boland LL, Ballantyne CM, Chambless LE. B vitamin status and inflammatory markers. Atherosclerosis. 2003 Jul;169(1):169-74.

Hunninghake DB, Ballantyne CM, Maccubbin DL, Shah AK, Gumbiner B, Mitchel YB. Comparative effects of simvastatin and atorvastatin in hypercholesterol-emic patients with characteristics of metabolic syndrome. Clin Ther. 2003 Jun;25(6):1670-86.

Jones PH. Comparing HMG-CoA reductase inhibitors. Clin Cardiol. 2003 Jan;26(1 Suppl 1):I15-20.

Jones PH. Atherosclerosis target of lipid-lowering therapy: is lower LDL cholesterol better? Am J Manag Care. 2003 Aug;Suppl:1, 4-5.

Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003 Jul 15;92(2):152-60.

Leonardson GR, Daniels MC, Ness FK, Kemper E, Mihura JL, Koplin BA, Foreyt JP. Validity and reliability of the general well-being schedule with northern plains American Indians diagnosed with type 2 diabetes mellitus. Psychol Rep. 2003 Aug;93(1):49-58.

Liu XM, Ensenat D, Wang H, Schafer AI, Durante W. Physiologic cyclic stretch inhibits apoptosis in vascular endothelium. FEBS Lett. 2003 Apr 24;541(1-3):52-6.

Ma K, Cilingiroglu M, Otvos JD, Ballantyne CM, Marian AJ, Chan L. Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2748-53.

McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW; STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin. 2003;19(8):689-98.

McPherson R, Jones PH. The metabolic syndrome and type 2 diabetes: role of the adipocyte. Curr Opin Lipidol. 2003 Dec;14(6):549-53.

Miller EA, Pankow JS, Millikan RC, Bray MS, Ballantyne CM, Bell DA, Heiss G, Li R. Glutathione-S-transferase genotypes, smoking, and their association with markers of inflammation, hemostasis, and endothelial function: the atherosclerosis risk in communities (ARIC) study. Atherosclerosis. 2003 Dec;171(2):265-72.

Morrisett J, Vick W, Sharma R, Lawrie G, Reardon M, Ezell E, Schwartz J, Hunter G, Gorenstein D. Discrimination of components in atherosclerotic plaques from human carotid endarterectomy specimens by magnetic resonance imaging ex vivo. Magn Reson Imaging. 2003 Jun;21(5):465-74.

Morrisett JD, Abdel-Fattah G, Kahan BD. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc. 2003 May;35(3 Suppl):143S-150S.

Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003 Oct 7;108(14):1664-72.

Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003 Oct 14;108(15):1772-8.

Neal RC, Jones PH. Lipid-lowering: can ezetimibe help close the treatment gap? Cleve Clin J Med. 2003 Sep;70(9):777-83.

Ponsin G, Qu SJ, Fan HZ, Pownall HJ. Structural and functional determinants of human plasma phospholipid transfer protein activity as revealed by site-directed mutagenesis of charged amino acids. Biochemistry. 2003 Apr 22;42(15):4444-51.

Poston WS, Reeves RS, Haddock CK, Stormer S, Balasubramanyam A, Satterwhite O, Taylor JE, Foreyt JP. Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification. Int J Obes Relat Metab Disord. 2003 Dec;27(12):1486-93.

Pownall HJ, Hamilton JA. Energy translocation across cell membranes and membrane models. Acta Physiol Scand. 2003 Aug;178(4):357-65.

Ruan H, Pownall HJ, Lodish HF. Troglitazone antagonizes tumor necrosis factor-alpha-induced reprogramming of adipocyte gene expression by inhibiting the transcriptional regulatory functions of NF-kappaB. J Biol Chem. 2003 Jul 25;278(30):28181-92.

Schmidt MI, Duncan BB, Vigo A, Pankow J, Ballantyne CM, Couper D, Brancati F, Folsom AR; ARIC Investigators. Detection of undiagnosed diabetes and other hyperglycemia states: the Atherosclerosis Risk in Communities Study. Diabetes Care. 2003 May;26(5):1338-43.

Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol. 2003 Jan 1;91(1):33-41.

Scott LW, Balasubramanyam A, Kimball KT, Aherns AK, Fordis CM Jr, Ballantyne CM. Long-term, randomized cliical trial of two diets in the metabolic syndrome and type 2 diabetes. Diabetes Care. 2003 Aug;26(8):2481-2.

Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, McGovern PG, Sharrett AR; Atherosclerosis Risk in Communities Study. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2003 Mar;34(3):623-31.

Sherman MB, Orlova EV, Decker GL, Chiu W, Pownall HJ. Structure of triglyceride-rich human low-density lipoproteins according to cryoelectron microscopy. Biochemistry. 2003 Dec 23;42(50):14988-93.

Tahir SA, Ren C, Timme TL, Gdor Y, Hoogeveen R, Morrisett JD, Frolov A, Ayala G, Wheeler TM, Thompson TC. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3653-9.

Taylor JE, Poston WS 2nd, Haddock CK, Blackburn GL, Heber D, Heymsfield SB, Foreyt JP. Psychometric characteristics of the General Well-Being Schedule (GWB) with African-American women. Qual Life Res. 2003 Feb;12(1):31-9.

Terre L, Poston WS, Foreyt J, St Jeor ST. Do somatic complaints predict subsequent symptoms of depression? Psychother Psychosom. 2003 Sep-Oct;72(5):261-7.

Wang H, Jiang X, Yang F, Gaubatz JW, Ma L, Magera MJ, Yang X, Berger PB, Durante W, Pownall HJ, Schafer AI. Hyperhomocysteinemia accelerates atherosclerosis in cystathionine beta-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation. Blood. 2003 May 15;101(10):3901-7.

Wu H, Prince JE, Brayton CF, Shah C, Zeve D, Gregory SH, Smith CW, Ballantyne CM. Host resistance of CD18 knockout mice against systemic infection with Listeria monocytogenes. Infect Immun. 2003 Oct;71(10):5986-93.

Wu KK, Aleksic N, Ballantyne CM, Ahn C, Juneja H, Boerwinkle E. Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease. Circulation. 2003 Apr 8;107(13):1729-32. Epub 2003 Mar 31.

Xydakis AM, Ballantyne CM. Role of non-high-density lipoprotein cholesterol in prevention of cardiovascular disease: updated evidence from clinical trials. Curr Opin Cardiol. 2003 Nov;18(6):503-9.

Xydakis AM, Jones PH. Use of Statins for Secondary Prevention. Curr Treat Options Cardiovasc Med. 2003 Feb;5(1):63-73.

Xydakis AM, Jones PH. Toxicity of antilipidemic agents: facts and fictions. Curr Atheroscler Rep. 2003 Sep;5(5):403-10.

Yang CY, Raya JL, Chen HH, Chen CH, Abe Y, Pownall HJ, Taylor AA, Smith CV. Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins. Arterioscler Thromb Vasc Biol. 2003 Jun 1;23(6):1083-90.

E-mail this page to a friend